Published in Medical Patent Law Weekly, September 5th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Solvay Pharmaceuticals, Inc.
Report 1: Solvay Pharmaceuticals, Inc., announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel(R) (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism. Solvay Pharmaceuticals also is seeking an additional indication for AndroGel in the treatment of Constitutional Delay in Growth and Puberty (CDGP) in male...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly